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Tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor that inhibits plasmin-dependent activation of
several metalloproteinases. Downregulation of TFPI-2 could thus enhance the invasive potential of neoplastic cells in several cancers,
including lung cancer. In this study, TFPI-2 mRNA was measured using a real-time PCR method in tumours of 59 patients with non-
small-cell lung cancer (NSCLC). Tumour TFPI-2 mRNA levels appeared well correlated with protein expression evaluated by
immunohistochemistry and were 4–120 times lower compared to those of nonaffected lung tissue in 22 cases (37%).
Hypermethylation of the TFPI-2 gene promoter was demonstrated by restriction enzyme-polymerase chain reaction in 12 of 40 cases
of NSCLC (30%), including nine of 17 for whom tumour TFPI-2 gene expression was lower than in noncancerous tissue. In contrast,
this epigenetic modification was shown in only three of 23 tumours in which no decrease in TFPI-2 synthesis was found (P¼0.016).
Decreased TFPI-2 gene expression and hypermethylation were more frequently associated with stages III or IV NSCLC (eight out of
10, P¼0.02) and the TFPI-2 gene promoter was more frequently hypermethylated in patients with lymph node metastases (eight out
of 16, P¼0.02). These results suggest that silencing of the TFPI-2 gene by hypermethylation might contribute to tumour progression
in NSCLC.
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Lung cancer is a major cause of death throughout the world and
develops slowly over many years from sequential accumulation of
multiple gene changes in pulmonary cells (Zochbauer-Muller et al,
2002). The major histological types of malignant lung tumours that
affect about 80% of patients are non-small-cell lung cancers
(NSCLC), which are divided into squamous cell carcinoma,
adenocarcinoma and mixed types (Travis et al, 1999). When lung
cancer is diagnosed at a localised stage, the 5-year survival is about
50%. In contrast, its prognosis is very poor when diagnosed with
lymph node involvement or metastases, and the 5-year survival is
then 8 and 3%, respectively (Etzioni et al, 2003). Several
mechanisms are involved in the spread of metastatic cancer cells
from the primary tumour, and degradation of the extracellular
matrix (ECM) is an important process involving a variety of
matrix-degrading proteinases. The most important proteolytic
ECM enzymes are metalloproteinases (MMPs), and upregulation of
MMPs expression has been reported to be strongly associated with
the progression of malignancy in several types of cancer, including
NSCLC (Cox et al, 1999; Egeblad and Werb, 2002). Metalloprotei-
nases are zinc-dependent endopeptidases secreted as inactive
proenzymes and some require activation by plasmin, a serine
proteinase. One potent inhibitor of plasmin within the ECM is
tissue factor pathway inhibitor-2 (TFPI-2), also called matrix-
associated serine protease inhibitor (MSPI). TFPI-2 is a 32kDa
Kunitz-type serine proteinase inhibitor also previously shown to
reduce tumour invasion (Konduri et al, 2000, 2001). By inhibiting
plasmin, TFPI-2 effectively decreases activation of MMP-1, MMP-3
and MMP-9 (Rao et al, 1999), and reduces the invasive potential of
several tumour cell lines including A549, an NSCLC cell line
(Lakka et al, 2000). The human TFPI-2 gene is located on
chromosome 7q22 (Miyagi et al, 1996) and its promoter contains a
CpG island region of at least 220bp that spans exon 1 and the three
transcription initiation sites. With a GþC content of about 77%
and an observed/expected presence of CpG40.85, this region also
coincides with the 5’ end of the minimal promoter (Hube et al,
2003a). CpG islands in normal cells are protected from methylation
by mechanisms that are poorly understood. In contrast, hyper-
methylation of CpG islands in the promoter region of tumour
suppressor genes is a well-known mechanism of gene silencing
that contributes to tumour progression in many cancers (Herman
and Baylin, 2003). Transcriptional silencing of the TFPI-2 gene by
promoter hypermethylation was recently demonstrated in human
glioma cells and choriocarcinoma cells (Hube et al, 2003b; Konduri
et al, 2003). The TFPI-2 gene might therefore be a candidate
tumour suppressor gene.
In this study, we first investigated TFPI-2 expression in several
histological types of NSCLC by a specific real-time polymerase
chain reaction (PCR) method. We then studied the methylation
status of human TFPI-2 promoter gene in a consecutive series of
lung tumours using methyl-sensitive restriction enzyme and
bisulfite genomic sequencing methods to evaluate whether
hypermethylation of the promoter gene might be responsible for
TFPI-2 gene downregulation.
Received 16 July 2004; revised 27 October 2004; accepted 2 November
2004; published online 1 February 2005
*Correspondence: Professor Y Gruel; E-mail: gruel@med.univ-tours.fr
British Journal of Cancer (2005) 92, 775–783
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sMATERIALS AND METHODS
Patients and samples
We analysed tissue samples collected in a prospective series of
59 patients with NSCLC who had undergone complete surgical
resection of the lung tumour as initial treatment (i.e. without prior
radiotherapy or chemotherapy) between January 2002 and May
2003 in our hospital (CHU Trousseau Tours, France). Tumoral and
nontumoral tissue samples were selected by a pathologist from
fresh surgical specimens from every patient, and immediately
stored in RNAlater (Ambion, Austin, TX, USA) until RNA or DNA
extraction and further analysis.
Histological diagnosis and grade of differentiation were
determined in accordance with the World Health Organization
(WHO) criteria for lung tumours (Travis et al, 1999) and
pathologic stage was based on the revised international system
(Mountain, 1997).
RNA extraction and cDNA synthesis
Total RNA was extracted from samples using the perfect RNA Mini
Kit (Eppendorf, Hambourg, Germany) according to the manufac-
turer’s instructions. The disruption and homogenisation of tissue
samples were first performed by grinding to a powder in liquid
nitrogen. Samples were then solubilised using a chaotropic
guanidinium isothiocyanate solution. The lysates were incubated
with an RNA-binding matrix, and finally total RNA was eluted
after washing with spin column chromatography. RNA yield and
purity were determined by spectrophotometry and only samples
with an A260/A280 ratio above 1.6 were kept for further experi-
ments. Four micrograms of total RNA were then reverse-
transcribed for 1h at 421Ci n1 buffer containing 125mM of each
deoxynucleotide triphosphate, 2.5mM random decamers (Ambion),
25U of RNase inhibitor and 20U of AMV Reverse Transcriptase
(Roche Diagnostics, Meylan, France).
Real-time quantitative PCR assay for TFPI-2 mRNA
The amount of TFPI-2 transcripts within lung tumours and
nonaffected tissues was assessed by real-time PCR using the icycler
iQ detection system (Bio-Rad, Ivry sur Seine, France). The primers
used to study TFPI-2 gene transcription were defined taking into
account the similarities between TFPI-1 and TFPI-2 and to avoid
hybridisation to homologous sequences (Table 1). Transcripts
specific for the gene encoding 18S ribosomal RNA were also
quantified for all samples using previously designed primers
(Wang et al, 2002). This gene was therefore used as an internal
control to evaluate the amount and quality of cDNA in every
sample.
Every TFPI-2-specific PCR was performed in a total reaction
volume of 25ml containing cDNA obtained from 100ng of total
RNA, 1 of Platinum Quantitative PCR SuperMix-UDG (Invitro-
gent, Cergy Pontoise, France), 0.32mM of each primer (Proligo,
Paris, France) and 0.2 of Sybr Green solution (Roche). To study
TFPI-2 gene expression, the PCR was initiated by a decontamina-
tion (501C for 2min) and denaturation step (951C, 2min), followed
by 35 cycles at 951C for 20s and at 671C for 40s. The PCR
conditions to quantify the amount of 18S transcripts were different
with regard to the amount of cDNA template (5ng), the primer
concentration (0.64mM), and 25 cycles (951C for 20s, and 651C for
40s) were performed. The melting curve was analysed for each
sample to check PCR specificity.
In order to express our results, specific standard curves were
established using purified PCR products of 750bp for TFPI-2 and
850bp for 18S. Decreasing amounts of these DNA fragments (from
2.5 10
7 to 2.5 10
1 copies and 2 10
8 to 2 10
5 copies for TFPI-
2 and 18S genes, respectively) were used for this purpose.
Each sample from either nonaffected lung or tumour tissue was
studied in duplicate and the Ct value obtained (threshold cycle)
allowed determination of the amount of the starting target message
using the specific standard curve.
The results for each sample (noncancerous or tumour tissue)
were expressed as the number of TFPI-2 mRNA copies for 10
7
copies of 18S. In addition, the ‘NTFPI-2’ value, that reflects TFPI-2
gene expression within a tumour compared to that of the
corresponding nonaffected (NA) lung, was calculated for each
patient as follows:
0N0
TFPI 2 ¼
TFPI   2tumour
18Stumour

TFPI   2NAlung
18SNAlung
Immunohistochemical localisation of TFPI-2
Formalin-fixed, paraffin-embedded samples of noncancerous
pulmonary tissue and lung tumour were studied for 22 patients.
In brief, 4-mm-thick tissue sections were deparaffinised, rehy-
drated, immersed in EDTA buffer and subjected to antigen
microwave retrieval. The primary antibody was a polyclonal
(rabbit) anti-human TFPI-2 IgG (Rao et al, 1996) used at 1/1000
dilution. Immunostaining for TFPI-2 was then revealed using a
standard streptavidin–biotin peroxidase complex (LSAB) method
with diaminobenzidine as a chromogen (ChemMatet Detection
kit, DakoCytomation, Denmark). Mature placenta tissue known to
express large amounts of TFPI-2 was used as a positive control,
with haematin counterstaining. Two independent observers
evaluated the topography and intensity of the staining. Staining
scores of stroma cells and tumour cells (ranging from 0 to 300)
were established by multiplying the staining intensity scaled from
0t o3( 0 ¼null, 1¼weak, 2¼moderate, and 3¼strong) by the
percentage of positive cells.
Dot blot analysis
Dot blot analysis was performed for 12 tumour samples expressing
either low (n¼6) or high (n¼6) levels of TFPI-2 mRNA. Tissue
samples were ground in liquid nitrogen, homogenised in 1ml of
TNC buffer (50mM Tris-HCl, 0.15mM NaCl, 10mM CaCl2, 0.02%
NaN3, 0.05% Brij35), and then centrifuged at 15000 r.p.m. for
15min. The protein concentration of each supernatant was
measured by Lowry’s method (Total Protein Kit, Sigma, Saint
Quentin Fallavier, France). A total of 2.5mg of total proteins (20ml)
were spotted on a nitrocellulose membrane and dried overnight.
The membrane was incubated for 1h with anti-TFPI-2 antibody
diluted 1/3000 in TNT buffer (100mM Tris HCl; 1.5 NaCl, 0.5%
Tween 20) and for 1h with peroxidase-labelled anti-rabbit IgG
(Sigma) after washing with TNT. Following exposure for 1min to
the Chemiluminescence Reagent Plus (Perkin-Elmer Biosystems,
Courtaboeuf, France), the membrane was drained, wrapped in
Saran-Wrap and exposed to autoradiography film (Kodak, NY,
Table 1 Oligonucleotide primers used in this study
Gene Sequences (50-30)
Products
PCR (bp)
TFPI-2 (q) Forward: AACGCCAACAATTTCTACACCT 125
Reverse: TACTTTTCTGTGGACCCCTCAC
18s (q) Forward: CGCGGTTCTATTTTGTTGGTTT 120
Reverse: TTCGCTCTGGTCCGTCTTG
TFPI-2 (m) Forward: ACAGTCCCCGTGCATGAATCAGCCAC 238
Reverse: AGTGCAGCCTCCGTCAGGAAAAGCAGC
q: primers used for quantitative PCR; m: primers used for methylation.
Expression of TFPI-2 gene in lung cancer
J Rollin et al
776
British Journal of Cancer (2005) 92(4), 775–783 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sUSA) for 1–2min in the dark. For each experiment, increasing
amounts of protein (0.0625, 0.125, 0.25, 0.5 and 1mg) extracted
from NCI-H23 (NSCLC cell line), previously identified as strongly
expressing TFPI-2, were systematically tested. A standard curve
was established defining that 1mg of NCI-H23 proteins contained
10 arbitrary units (AU) of TFPI-2. Results were then expressed in
AU per microgram of protein after measurement of spot intensities
by the Multi Analyst/Macintosh software (Biorad).
Methylation analysis of TFPI-2 promoter
To determine the methylation status of the TFPI-2 promoter, a
restriction enzyme-related polymerase chain reaction (RE-PCR)
method was first applied to the study of samples collected from 40
patients for whom remaining material was available. Preparation
of genomic DNA from tumour and nonaffected lung samples was
performed using a DNA purification kit (Qiagen, Courtaboeuf,
France). Every sample was lysed using proteinase K. DNA in the
lysate was then bound to a silica-gel membrane and eluted in water
after washing. Genomic DNA (4mg) was then predigested with 40U
HindIII (Promega, Lyon, France) overnight at 371C and 1mg of the
restricted DNA was incubated for 16h at 371C with 10U EagIo r
5UHgaI (Ozyme, Saint Quentin Yvelines, France). For the PCR, all
restriction endonuclease-treated samples were diluted 1:20 in
water. PCR was performed in a 25ml reaction containing 10mM
Tris-HCl pH 9.0, 50mM KCl, 0.01% (wv
 1) gelatin, 1.5mM MgCl2,
0.1% Triton X-100, 50mM of each deoxynucleotide triphosphate,
0.5U of Super Taq DNA polymerase (ATGC Biotechnologies,
Noisy Le Grand, France), and 1mM of forward and reverse
synthesised oligonucleotide primers (Table 1) (Proligo). GC-rich
solution (Roche Diagnostics) was also used to facilitate amplifica-
tion of GC-rich sequences. PCR was set up in a GeneAmp PCR
system 2400 (Applied Biosystems, Courtaboeuf, France) with a
touchdown programme to increase the specificity. The tempera-
ture profile was 2min at 951C followed by amplification for 20
cycles with a 0.51C decrease in the annealing temperature after
each cycle. The starting cycle consisted of 30s at 951C, 30s at 701C,
and 30s at 721C. In total, 20 additional cycles were performed, with
a fixed annealing temperature of 601C, and a final extension for
10min at 721C. PCR products were then analysed by electrophor-
esis through 1.6% agarose gel in TBE buffer (90mM Tris-HCl,
90mM borate acid, 2.5mM EDTA) containing 1mgml
 1 ethidium
bromide. Finally, PCR products were visualised by UV trans-
illumination (Gel Doc 1000 system, Bio Rad) and band intensities
were measured (Multi analyst/Macintosh software). The TFPI-2
gene promoter was considered as hypermethylated within the
tumour when the band intensity measured after RE-PCR
performed with DNA extracted from the cancerous biopsy was at
least twice as high as those obtained after studying DNA isolated
from the nonaffected lung.
The methylation status of each CpG dinucleotide within a 250bp
region ( 207/48 from translation start site) of the TFPI-2
promoter was also studied by bisulphite genomic sequencing in
seven patients selected as described below according to the results
obtained by real-time PCR (NTFPI-2 values) and RE-PCR. Genomic
DNA was converted by sodium bisulphite as recently described by
Hube et al (2003b). Briefly, 4mg of DNA were digested overnight
with 5U HindIII and then denatured with 0.3 M NaOH. Sodium
bisulphite solution was added at a final concentration of 3 M and
incubated for 18h at 551C, pH 5.0, in the dark with 20mM
hydroquinone. DNA was desalted with the GFX PCR DNA and
gel purification Kit (Amersham Pharmacia Biotech Europe GMBH,
Paris, France) and then desulphonated with 0.3 M NaOH before
being precipitated by ethanol. Finally, DNA was amplified using
nested PCR as previously described (Hube et al, 2003b) and the
products obtained were then purified and cloned into pCR 2.1
TOPO vectors (Invitrogen). Three clones were selected after each
experiment and sequenced to determine the methylation status in
every sample. Choriocarcinoma JAR cells and trophoblast cells
isolated from normal placentas (Hube et al, 2003c) were also
studied as positive (i.e. hypermethylated) and negative controls for
every experiment (RE-PCR or bisulphite genomic sequencing).
Statistical analysis
The Sign test was used to evaluate the distribution of TFPI-2
mRNA levels in nonaffected lung tissues and tumour samples. The
staining scores of immunohistochemistry were compared using the
Mann–Whitney U-test. Analyses of the association between TFPI-
2 mRNA expression, gene methylation status and clinicopatholo-
gical feactures were performed with Pearson’s w
2. All P-values
obtained were considered as significant when p0.05.
RESULTS
TFPI-2 mRNA expression in NSCLC
The real-time PCR developed to study TFPI-2 gene expression was
first evaluated with varying amounts of a 750-bp TFPI-2 cDNA
used as template. A strong linear relationship between the Ct and
the log of the number of copies was consistently demonstrated
(R
2X0.99). The efficiency of the reaction ranged from 92 to 97%,
with low intra- and inter-assay variations (0.8 and 2.3%,
respectively). Similar results were recorded with the real-time
PCR developed to study the 18S gene (efficiency 95.7% with intra-
and inter-assay variations of 1.4 and 2.4% respectively).
Highly variable amounts of TFPI-2 mRNA were measured within
both the nonaffected lung (32–20400 copies/10
7 18S RNA) and the
tumour (15–336000 copies) and the distribution of values
obtained was similar in both categories of tissue (P¼0.5)
(Figure 1). Four samples (i.e. two from the nonaffected lung and
two from the tumour) were analysed for 25 patients, and the
number of TFPI-2 mRNA copies measured within two biopsies
obtained from the same tissue never varied more than four-fold
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Figure 1 TFPI-2 gene expression in nonaffected lung tissue (N) and non-
small-cell lung tumours (T). Each point is representative of at least two
duplicates.
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s(mean¼1.8, and range¼1.1–3.9). The amount of TFPI-2 mRNA
within the tumour was therefore considered to be significantly
different to the amount in the noncancerous lung when the NTFPI-2
value was either 44 (i.e. increased) or o0.25 (i.e. decreased). Such
a difference in TFPI-2 gene expression between the tumour and the
corresponding noncancerous lung was found in 34 patients
(Figure 2A). Indeed, NTFPI-2 values were at least four times higher
in 12 cases (20%) and in contrast significantly lower than 0.25 in
22 patients (37%). In this latter group of patients, the relative
decrease in TFPI-2 gene expression varied between patients,
ranging between 4- and 120-fold compared to noncancerous lungs
(with NTFPI-2 values varying between 0.25 and 0.008). It was also
observed in both stage I–II NSCLC (11/33, 33%) and stage III–IV
(11/26, 42%). This downregulation of TFPI-2 gene was observed in
both adenocarcinomas (11/35, 31%) and squamous cell carcino-
mas (9/16, 56%) (Figure 2B). On the other hand, this relative
decrease in TFPI-2 mRNA levels was also more frequent in cases of
lymph node invasion (48 vs 30%) but the difference was not
significant (Figure 2C).
TFPI-2 protein expression in primary lung tumours
Immunostaining for TFPI-2 protein was studied in lung samples of
two groups of patients defined according to TFPI-2 gene
expression within the tumour. The number of TFPI-2 transcripts
within the tumour was higher than 2500 for 10
7 18S RNA copies in
11 cases (‘High TFPI-2’ group), while it was lower than 100 in the
11 others (‘Low TFPI-2’ group).
TFPI-2 was highly expressed in bronchial epithelium and
endothelium cells of noncancerous lungs as well as in alveolar
macrophages (Figure 3A). Within tumours, both stroma and
cancerous cells appeared to synthesise varying amounts of TFPI-2
protein (Figure 3B–D), and the staining score was well correlated
with the number of TFPI-2 mRNA copies measured by real-time
PCR (r¼0.65, Po0.01). In addition, the staining scores obtained
for the 11 tumours expressing limited amounts of TFPI-2 mRNA
were also significantly lower than those of the ‘High TFPI-2’ group
(Figure 3D).
Dot blot analysis performed for 12 selected lung tumours also
showed that TFPI-2 protein levels were higher in biopsies
expressing high levels of TFPI-2 mRNA (range¼0.7–2.2AUmg
 1
vs 0.12–0.28AUmg
 1 in ‘low TFPI-2’ tumours, Figure 4).
Methylation status of promoter TFPI-2 gene in NSCLC
The methylation status of TFPI-2 promoter within the tumour was
studied by RE-PCR using two different methyl-sensitive restriction
enzymes, HgaI and EagI. When the TFPI-2 gene promoter was not
methylated, such as in normal trophoblast cells, a faint band was
obtained after PCR with HgaI- or EagI-digested DNA (Figure 5A).
In contrast, a strong band was observed when the TFPI-2 promoter
was hypermethylated, such as in choriocarcinoma JAR cells chosen
in every experiment as positive controls. Band intensity was
therefore similar with these cells, whether genomic DNA was
treated by HgaIo rE agI or not. Lung samples of 40 patients with
primary NSCLC were studied using this RE-PCR method. In 12
cases (30%), the band intensity after PCR performed following
digestion of tumour DNA by HgaI and EagI was at least twice as
high as the level measured after identical treatment of nonaffected
tissue DNA (as illustrated for one case, Pat 1, Figure 5A). In
contrast, the band intensities of PCR products were similarly
reduced after RE-PCR on tumour and noncancerous tissue DNA in
28 patients compared to the intensity of undigested DNA (see Pat
2, Figure 5A), and this result supported the unmethylated status of
TFPI-2 gene promoter in these cases. When these results were
compared to those obtained by real-time PCR, the TFPI-2 gene
promoter was hypermethylated in nine of the 17 lung tumours
(53%) for which gene expression was lower than in noncancerous
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Figure 2 Relative TFPI-2 gene expression in NSCL tumours. The
‘NTFPI-2’ values are shown according to the stage of the disease (panel A),
the histological type of the lung cancer: AC¼adenocarcinoma;
SCC¼squamous cell carcinoma; others¼other histological subtypes
(panel B), and the presence (N1–N2) or absence (NO) of lymph node
metastases (panel C).
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stissue. In contrast, this epigenetic modification was demonstrated
by RE-PCR in only three of the 23 lung tumours (13%) in which no
decrease in TFPI-2 mRNA synthesis was found (P¼0.016,
Figure 5B).
To validate these results obtained by RE-PCR, bisulphite
genomic sequencing was then used to determine the precise
methylation status of each of the 28 CpG dinucleotides within a
250bp region of the TFPI-2 gene promoter in selected samples.
Treatment of genomic DNA by sodium bisulphite converts
unmethylated cytosines to uracils while 5-methylcytosines remain
unmodified. The methylation profile of the TFPI-2 gene promoter
sequence could thus be precisely defined by sequencing PCR
products obtained from bisulphite-treated DNA. Seven primary
NSCLC tumour samples and seven nonaffected biopsies obtained
from the same patients were examined using this method, and
these samples were chosen according to TFPI-2 gene expression
(real-time PCR) and methylation status as evaluated by RE-PCR
(Figure 6). For all patients studied, the results of bisulphite
genomic sequencing were in accordance with those obtained by
the RE-PCR method. In four patients TFPI-2 gene expression was
decreased within the tumour compared to nonaffected tissue, and
in two of them 26 of 28 CpG dinucleotides were methylated. In
contrast, for the two others, the TFPI-2 gene promoter was
unmethylated in both the tumour and noncancerous tissues. A
similar unmethylated status of the promoter sequence was also
demonstrated in two patients for whom TFPI-2 gene expression
was not decreased (Pat 5) or increased (Pat 6) within the lung
tumour. However, in one case, a high rate of promoter methylation
was identified, although TFPI-2 mRNA levels were comparable in
nonaffected lung tissue and the tumour.
TFPI-2 gene expression and promoter methylation
compared to clinicopathologic features in NSCLC
No significant difference in TFPI-2 gene expression or promoter
methylation was found according to sex, smoking status, or the
histological type of lung cancer (Table 2). In addition, the
frequency of reduced TFPI-2 gene expression was not statistically
different between T1–T2 and T3–T4 lung tumours. In contrast,
the TFPI-2 promoter was hypermethylated in eight of 16 patients
for whom lymph node involvement was demonstrated, compared
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(n = 11)
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D
Figure 3 Immunostaining of TFPI-2 in primary tumour and noncancer-
ous tissues. (A) Noncancerous lung: TFPI-2 staining of macrophages (M),
bronchial epithelium (BE) and endothelial cells (EC). (B) Squamous cell
carcinoma with no TFPI-2 staining in tumour cells (T) and significant staining
in stroma cells (S). (C) Adenocarcinoma with significant TFPI-2 staining in
tumour cells. Peroxidase technique using polyclonal rabbit antibody specific
to human TFPI-2. Haematin counterstaining, original magnification  200.
(D) Staining scores in tumour cells and/or stroma cells of NSCLC samples
with TFPI-2 mRNA levels o100 (‘low TFPI-2’) or 42500 copies (‘high
TFPI-2’). NS¼non significant.
0 0.625 1.25 2.5 5 10 AU
AU g-1 
AU g-1
Standard
'High TFPI-2'
'Low TFPI-2'
1 2.2 0.7 0.8 1.9 1.3
0.28 0.16 0.12 0.16 0.24 0.20
Figure 4 Dot blot analysis. TFPI-2 protein expression in 12 NSCLC with
TFPI-2 mRNA level 42500 (‘high TFPI-2’, n¼6) or o100 copies (‘low
TFPI-2’, n¼6). Results are expressed in AU/mg of total protein according
to a standard curve obtained with increasing amounts of proteins from
NCI-H23 (line 1). These data are representative of three independent
experiments.
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sto four of 24 with N0 status (P¼0.02). Moreover, decreased
expression of TFPI-2 associated with hypermethylation of the gene
promoter was found in eight out of 10 patients with advanced stage
of cancer (III or IV) compared to only one out of seven with stage I
or II NSCLC (P¼0.02).
DISCUSSION
A relative decrease in TFPI-2 mRNA synthesis was demonstrated
in this study in 37% of NSCLC using a real-time reverse
transcription–PCR (RT–PCR) assay. Real-time PCR is a sensitive
and reproducible method that represents a significant advance for
the analysis of TFPI-2 gene expression compared to Northern blot
analysis (Izumi et al, 2000), semiquantitative RT–PCR (Iochmann
et al, 1999) and competitive RT–PCR (Iochmann et al, 2002). In
particular, this procedure allowed us to detect significant levels of
TFPI-2 mRNA in noncancerous lung tissue, whereas such
expression had not been previously demonstrated by RNA blot
hybridisation (Izumi et al, 2000). Quantification of TFPI-2 mRNA
levels using real-time PCR was found to be highly reproducible,
with low inter- and intra-assay variations. However, differences in
TFPI-2 mRNA levels were recorded when we analysed two biopsies
sampled within the same tissue (either nonaffected lung or
tumour), although they were never more than four-fold. These
differences were probably due to heterogeneity of cell composition
from one sample to another since different cells within both
noncancerous lung tissue and tumours can synthesise TFPI-2, as
shown by immunohistochemistry. A decrease in TFPI-2 mRNA
level measured by Northern blotting and in situ hybridisation has
previously been demonstrated in other cancers, particularly in
human gliomas (Rao et al, 2001). Moreover, TFPI-2 protein is
undetectable by Western blotting in high-grade glioblastomas.
TFPI-2 protein synthesis has also recently been studied by
immunohistochemical procedures in other different tumours
(laryngeal, breast, gastric, colon, pancreatic, renal and endometrial
cancer) and was shown to decrease when the degree of malignancy
increased (Wojtukiewicz et al, 2003). As demonstrated by
immunohistochemistry, TFPI-2 is mainly synthesised in noncan-
cerous lung by bronchial epithelial cells and alveolar macrophages.
Within tumours, both stroma cells and cancerous cells were shown
to express varying amounts of TFPI-2 protein, and a good
correlation between the staining score and mRNA levels measured
by real-time PCR was found. Dot blot analysis performed on
selected samples also confirmed that TFPI-2 protein levels were
lower in tumours in which few transcripts of TFPI-2 gene were
measured. In a few tumours, TFPI-2 was almost undetectable in
cancerous cells, contributing to the lower protein expression
measured for samples expressing not many TFPI-2 mRNA copies.
We then specifically focused on the methylation status of the
TFPI-2 gene promoter in order to understand why TFPI-2 mRNA
levels were decreased in at least one third of NSCLC. We first
employed RE-PCR, which is a rapid assay that allowed us to
evaluate the methylation status of three CpG sites among the 28
present in the TFPI-2 gene promoter sequence. Hypermethylation
of the TFPI-2 gene promoter was thus demonstrated in 12 of the 40
cases of NSCLC that were studied (30%), including nine for whom
TFPI-2 gene expression was decreased compared to noncancerous
lungs. To validate the results obtained by RE-PCR, we also
analysed lung samples from seven selected patients using the
bisulphite genomic sequencing method. Despite being time-
consuming, this procedure has the advantage of making the
analysis of all CpG sites present within the sequence of interest
feasible, and confirmed the results obtained by RE-PCR. In
addition, concordant results were also obtained after studying
noncancerous and cancerous lung samples collected in these seven
patients by a methylation-specific PCR method (data not shown).
The frequency of TFPI-2 gene promoter methylation (30%) was
relatively high compared to frequencies previously published for
other methylated genes in primary lung tumours such as MGMT,
DAPK, E-cadherin, RASSF1A, TIMP-3 and p16 (Esteller et al, 1999;
Tang et al, 2000; Zochbauer-Muller et al, 2002; Yanagawa et al,
2003). Silencing of the TFPI-2 gene associated with hypermethyla-
tion of the promoter has recently been described in several cancer
cell lines derived from choriocarcinoma (Hube et al, 2003b),
glioma (Konduri et al, 2003), fibrosarcoma, breast and prostate
cancers (Rao et al, 2003). However, this mechanism is probably
not the only cause of TFPI-2 gene silencing since hypermethylation
of the TFPI-2 promoter was not demonstrated in eight patients in
whom TFPI-2 expression within tumours was decreased. Little is
known regarding regulation of transcription of the TFPI-2 gene,
but it was recently shown that its silencing could be achieved
despite the absence of methylation in both exon 1 and sequences
upstream from the transcription initiation site (Rao et al, 2003).
Histone deacetylation is another potential mechanism for TFPI-2
gene silencing in cancer cells since trichostatin A, which inhibits
the histone deacetylase, was shown to be effective in inducing
TFPI-2 mRNA synthesis in glioma cells (Konduri et al, 2003). The
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Figure 5 Methylation analysis of TFPI-2 gene promoter in NSCLC using
RE-PCR. (A) Representative data obtained in two patients are presented
(Pat 1: hypermethylated and Pat 2: unmethylated). N¼noncancerous
tissue; T¼lung tumour. JAR¼choriocarcinoma cells (i.e. hypermethylated
positive control), TC¼normal trophoblast cells (i.e. unmethylated control)
and M¼fX174 RF DNA/HaeIII DNA. Genomic DNA was digested
before PCR with Hgal or Eagl, and results obtained with undigested DNA
are also presented. (B) Methylation status of TFPI-2 promoter in relation to
relative expression of the gene within lung tumours of 40 patients.
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1996), and deletions of the 7q region have been described in
several malignant tumours (Atkin and Baker, 1993), but this
chromosomal abnormality is not a frequent feature of NSCLC. In
contrast, gain in 7q has been associated with higher stages of lung
tumours and positive nodal involvement on higher tumour grades
(Pei et al, 2001). On the other hand, as supported by findings
obtained with a human fibrosarcoma cell line (HT-1080) and
normal human fibroblasts, the RAS oncogene, which can be
mutated in NSCLC (Zochbauer-Muller et al, 2002), may also
contribute to a downregulation of TFPI-2 gene expression (Izumi
et al, 2000). This hypothesis deserves further study since it was
recently shown that regulation of the human TFPI-2 gene is
mediated through the Ras/Raf/MEK/ERK pathway (Kast et al,
2003). We also found that the TFPI-2 gene promoter sequence was
hypermethylated in three of 23 cases of NSCLC although mRNA
levels within the tumours were not decreased. Incomplete
digestion of DNA-sensitive sites by restriction enzyme is a well-
known limitation of RE-PCR (Fraga and Esteller, 2002), but this
technique also possibly detected either tumour cells having only
one methylated allele or a subfraction of methylated cells within
samples. Finally, we also found that TFPI-2 gene promoter was
more frequently hypermethylated in patients with lymph node
metastases. In addition, decreased TFPI-2 gene expression and
promoter hypermethylation were more frequently associated with
advanced stages (i.e. III and IV) of lung cancer. During tumour
progression, malignant cells may invade adjacent tissues, particu-
larly lymph nodes, and increased plasmin activity in the vicinity of
malignant cells, with subsequent activation of MMPs and ECM
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Figure 6 Methylation analysis of TFPI-2 gene promoter in lung cancer and noncancerous tissues using a bisulphite genomic sequencing method. The CpG
methylation status of a 250bp region ( 207/þ48 from translation start site) of TFPI-2 promoter was studied by the bisulphite genomic sequencing method
in seven patients selected according to TFPI-2 expression and results of RE-PCR (N¼nonaffected lung, T¼tumour). Numbers at the top (1 to 28)
correspond to the relative position of CpG sites in this region. Restriction sites for Eagl and Hgal are also indicated. Each row of circles shows sequencing
data obtained from three different clones. Each circle represents a single CpG site that was either nonmethylated (O) or methylated ( ¼one out of three
clones, ¼two out of three clones, K¼three out of three clones).
Table 2 Relationship between TFPI-2 gene expression, promoter
methylation status and clinicopathological features
Features NTFP1-2o0.25
Hypermethylation
of TFPI-2
NTFPI-2o0.25 and
hypermethylation
Sex
M 18/50 (36%) 10/34 (29%) 8/15 (53%)
F 4/9 (44%) 2/6 (33%) 1/2 (50)
Smoking
Yes 19/47 (40%) 11/32 (34%) 9/15 (60%)
No 3/9 (33%) 1/6 (17%) 0/2 (0%)
Tumour
status
T1–T2 21/48 (43%) 11/31 (35%) 8/16 (50%)
T3–T4 1/10 (10%) 1/9 (11%) 1/1 (100%)
Nodal
status
N0 10/33 (30%) 4/24 (17%)
P¼0.02
2/7 (12%)
N1–N2 12/25 (48%) 8/16 (50%) 7/10 (70%)
Stage
I–II 11/33 (33%) 1/21 (19%) 1/7 (14%)
P¼0.02 III–IV 11/26 (42%) 8/19 (42%) 8/10 (80%)
J
Histology
AC 11/35 (31%) 7/24 (29%) 5/9 (56%)
SCC 9/16 (56%) 3/11 (27%) 3/6 (50%)
Others 2/8 (25%) 2/5 (40%) 1/2 (50%)
Total 22/59 (37%) 12/40 (30%) 9/17 (53%)
For each feature, the number and percentage (%) of patients are indicated. AC:
adenocarcinoma; SCC: squamous cell carcinoma.
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1999, 2000; Konduri et al, 2000). Reduced synthesis in NSCLC of
TFPI-2, a potent inhibitor of plasmin, might therefore contribute
to tumour invasiveness and metastases in vivo. This role of TFPI-2
in cancer invasion was recently supported by injecting fibrosarco-
ma cell lines expressing active or inactive forms of TFPI-2 in mice
(Chand et al, 2004). Human TFPI-2 could also regulate tumour
angiogenesis by reducing synthesis of the VEGF receptor and affect
the expression of several genes involved in oncogenesis, invasion
and apoptosis (Chand et al, 2004). In addition, TFPI-2 could also
influence apoptosis of malignant cells by decreasing the activity of
caspases 9 and 3 (Tasiou et al, 2001). Whether or not these
mechanisms are also regulated within the lung by TFPI-2 has to be
evaluated, but our findings strongly suggest that low expression of
the TFPI-2 gene by tumour or stroma cells could also favour the
development of NSCLC and metastases in vivo. On the other hand,
the underlying mechanisms for the de novo methylation of the
TFPI-2 gene in lung cancer cells also remain to be determined.
Several mechanisms have been proposed (Tycko, 2000), including
overexpression of DNA methyltransferases, increased methylation
secondary to overexpression of transcription repressors or loss of
transcriptional factors, and intra-allelic transfer of methylation via
gene pairing, but all these hypotheses need to be further studied in
lung cancer. Silencing of tumour suppressor genes by hyper-
methylation is a major epigenetic change that contributes to
tumour progression. The results obtained in this study indicate
that this process can be involved in the downregulation of TFPI-2
expression during NSCLC.
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